International Journal of Clinical Oncology最新文献

{"title":"Prognostic prediction using recursive partitioning analysis of patients undergoing salvage surgery for locally recurrent oral squamous cell carcinoma.","authors":"Toshihiko Sakai, Go Omura, Kohtaro Eguchi, Azusa Sakai, Yoshifumi Matsumoto, Chihiro Fushimi, Seiichi Yoshimoto","doi":"10.1007/s10147-025-02739-9","DOIUrl":"10.1007/s10147-025-02739-9","url":null,"abstract":"<p><strong>Background: </strong>The prognosis of patients with locally recurrent oral cavity squamous cell carcinoma (LR-OCSCC) remains poor even when salvage surgery can be performed. Therefore, the current study aimed to identify adverse prognostic factors in these patients and use recursive partitioning analysis (RPA), a machine learning statistical method, to develop a prognostic classification based on these factors.</p><p><strong>Methods: </strong>The clinical data of 75 patients who underwent salvage surgery for LR-OCSCC at the National Cancer Center between 2010 and 2022 were retrospectively reviewed. Prognostic factors were analyzed using Cox proportional hazards regression models. Patients were classified by survival outcomes using RPA. Survival rates were determined using the Kaplan-Meier method.</p><p><strong>Results: </strong>The 3-year overall survival (OS) and locoregional recurrence rates for all patients who underwent salvage surgery were 53.4% and 32.7%, respectively. The univariate Cox proportional hazards regression analysis identified concurrent regional recurrence, previous history of radiotherapy to the neck, and recurrence within 12 months from initial treatment as adverse prognostic factors. RPA was performed using these variables and patients were classified into low-, intermediate-, and high-risk groups based on a combination of concurrent regional recurrence and time to recurrence. The 3-year OS rates for the low-, intermediate-, and high-risk groups were 73.3%, 53.3%, and 24.4%, respectively.</p><p><strong>Conclusion: </strong>A novel prognostic classification for LR-OCSCC salvage surgery was developed to facilitate development of treatment strategies and identification of patients that would not benefit from this procedure.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1118-1126"},"PeriodicalIF":2.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simple definition of biologically borderline resectable colorectal liver metastases based on early surgical failure.","authors":"Kenei Furukawa, Masashi Tsunematsu, Koichiro Haruki, Shinji Onda, Kyohei Abe, Michinori Matsumoto, Tomohiko Taniai, Mitsuru Yanagaki, Yoichi Toyama, Toru Ikegami","doi":"10.1007/s10147-025-02752-y","DOIUrl":"10.1007/s10147-025-02752-y","url":null,"abstract":"<p><strong>Background: </strong>The benefit of neoadjuvant chemotherapy (NAC) in patients with resectable colorectal liver metastasis (CRLM) is debatable. This study aimed to establish a definition of biologically borderline resectable CRLM based on early surgical failure.</p><p><strong>Methods: </strong>One hundred forty-two patients who underwent upfront surgery for resectable CRLM were examined. Potential predictors of early surgical failure were investigated to establish a definition of biologically borderline resectable CRLM. The impact of NAC on overall survival (OS) in patients with borderline resectable CRLM was examined, as were predictors of OS.</p><p><strong>Results: </strong>Extrahepatic lesions (p < 0.01) and tumor ≥ 30 mm with carcinoembryonic antigen (CEA) concentration ≥ 20 ng/mL (p = 0.02) were independent predictors of early surgical failure. Borderline resectable CRLM was defined as extrahepatic lesions or tumor size ≥ 30 mm with CEA concentration ≥ 20 ng/mL. Fifty-eight patients had borderline resectable CRLM. Three-year OS was significantly higher in borderline resectable CRLM patients who received NAC than in those who did not (71.8% vs. 52.7%) and 5-year survival was also significantly higher in this group (62.8% vs. 25.5%).</p><p><strong>Conclusion: </strong>We have proposed a simple definition of biologically borderline resectable CRLM based on early surgical failure. NAC could be a good indication for patients who met the definition.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1193-1200"},"PeriodicalIF":2.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting resectability of biliary tract cancers, in the triplet drug therapy era with immune checkpoint inhibitors.","authors":"Shogo Kobayashi, Daisaku Yamada, Yuichiro Doki, Hidetoshi Eguchi","doi":"10.1007/s10147-025-02769-3","DOIUrl":"10.1007/s10147-025-02769-3","url":null,"abstract":"<p><p>Biliary tract cancers (BTCs) include intrahepatic, perihilar, distal cholangiocarcinoma, gallbladder cancer, and sometimes papillary Vater cancer. The incidence of BTCs varies worldwide (0.3-85.0/100,000 population). In Japan, the incidence is lowest, but it is increasing (22,000 cases/ year). The 5-year overall survival (OS) in patients with localized BTC is approximately 60%, which is better than that in liver or pancreatic cancer, but is < 5% in patients with metastatic cancers. Surgery requires liver and pancreas surgery with vascular reconstruction, and is associated with a high perioperative mortality rate (> 2%) relative to other cancer surgeries (< 1%). As an adjuvant therapy, fluorouracil prodrugs are effective for improving OS (hazard ratio [HR] 0.69-0.81); however, in patients who receive major hepatectomy, the completion rate is reportedly low (60%). Since 2010, gemcitabine + cisplatin (GC) has become the first-line therapy for unresectable lesions. Subsequently, in 2023-2024 three triplet regimens were reported: GC + S-1(tegafur-gimeracil-oteracil), GC + durvalumab (an anti-PD-L1 antibody), and GC + pembrolizumab (an anti-PD-1 antibody). HRs for OS were 0.79-0.83, objective response rates were 27-42% (GC, 15-29%), and tumor control rates were 75-85% (GC, 62-83%) with small increases in adverse events. In this review, considering the eligibility criteria of currently ongoing neoadjuvant studies, we report two borderline resectable cases with a discussion on resectability. Owing to the high-risk nature of the surgery and to avoid early recurrence due to subclinical metastasis during postoperative recovery, these three triplet regimens for unresectable tumors may change the concept of resectability in BTC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1060-1068"},"PeriodicalIF":2.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan: the EN-hance study.","authors":"Toru Aoyama, Akira Ooki, Koji Oba, Kazuhiro Nishikawa, Ryohei Kawabata, Michitaka Honda, Hiromichi Maeda, Mitsuro Kanda, Keiji Sugiyama, Akitaka Makiyama, Kenki Segami, Masazumi Takahashi, Yoshiaki Shindo, Tsutomu Namikawa, Takashi Oshima, Aya Katayama, Kazuhito Shiosakai, Junichi Sakamoto","doi":"10.1007/s10147-025-02748-8","DOIUrl":"10.1007/s10147-025-02748-8","url":null,"abstract":"<p><strong>Background: </strong>Trastuzumab deruxtecan (T-DXd) has been approved for the treatment of human epidermal growth factor receptor-2 (HER2)-positive gastric cancer and other indications in several countries and is considered moderately or highly emetogenic. The management of nausea and vomiting associated with T-DXd treatment has not been fully evaluated and the effectiveness of conventional prophylaxis remains unknown.</p><p><strong>Methods: </strong>This open-label, randomized, multicenter, phase 2 study aimed to investigate the optimal antiemetic therapy for Japanese patients with gastric cancer undergoing T-DXd treatment. Patients were randomized to a doublet regimen group (dexamethasone and palonosetron) or triplet regimen group (aprepitant, dexamethasone, and palonosetron) at a ratio of one to one, stratified by sex, gastrectomy status, and study institution. Both antiemetic treatments were administered from day 1 before T-DXd administration, and emetic events and nausea were observed for 21 days. The primary endpoint was the antiemetic complete response (CR) rate to assess control for emetic events based on voluntary patient-reported outcomes (PROs) during cycle 1 (1-21 days).</p><p><strong>Results: </strong>Of the 60 enrolled patients, 58 were eligible for inclusion in this analysis (29 patients in each regimen group). The overall CR rates for the doublet and triplet regimens were 41.4% (12/29 patients) and 37.9% (11/29 patients), respectively, and neither regimen met the pre-specified threshold (> 18/29 patients). The CR rate in the acute phase (0-24 h) was 86.2% (25/29 patients) for both regimens, and the CR rates in the delayed phase (2-21 days) were 41.4% (12/29 patients) and 37.9% (11/29 patients) for the doublet and triplet regimens, respectively.</p><p><strong>Conclusions: </strong>Given that the primary endpoint was not met, further research is needed to better characterize nausea and vomiting with T-DXd to tailor an anti-emetic regimen that suits the needs of the patients.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1162-1173"},"PeriodicalIF":2.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12122603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term results of dynamic tumor-tracking stereotactic body radiotherapy with real-time monitoring using a gimbal-mounted linac for liver tumors: a multicenter observational study.","authors":"Yusuke Iizuka, Minoru Inoue, Masaki Kokubo, Takashi Sakamoto, Keiko Nemoto Murofushi, Toshiyuki Imagumbai, Takuya Shimizuguchi, Masahiro Hiraoka, Takashi Mizowaki","doi":"10.1007/s10147-025-02740-2","DOIUrl":"10.1007/s10147-025-02740-2","url":null,"abstract":"<p><strong>Background: </strong>Despite advancements in liver tumor treatments, a persistent need remains for minimally invasive therapies with high efficacy and long-term outcomes. In a previous multicenter phase II study, the safety and efficacy of dynamic tumor-tracking stereotactic body radiotherapy with real-time monitoring of liver tumors were evaluated using a gimbal-mounted system. Herein, we report the updated long-term results of this technique.</p><p><strong>Methods: </strong>This observational study examined patients with a single liver tumor, respiratory movement of at least 10 mm, performance status of 0-2, and Child-Pugh score of < 9. Patients who agreed to participate in the trial underwent dynamic tumor-tracking stereotactic body radiotherapy (prescribed dose, 40 Gy in five fractions for the planning target volume [D₉₅]; 70% of the maximum dose). The primary endpoint was the 4-year overall survival rate. Secondary endpoints included 4-year local control and progression-free survival rates and the incidence of adverse events.</p><p><strong>Results: </strong>Between September 2015 and March 2019, 48 patients (median age, 74 years; median tumor diameter, 17.5 mm) underwent dynamic tumor-tracking stereotactic body radiotherapy. All lesions were successfully treated (hepatocellular carcinoma, 39 patients; liver metastases, 9 patients). The median observation period was 46 months, and the 4-year overall survival, local control, and progression-free survival rates were 67.4%, 97.9%, and 29.1%, respectively. Eight patients had grade 3 hepatobiliary enzyme elevation, hematologic toxicity, or hyponatremia; none had grade ≥ 4 adverse events.</p><p><strong>Conclusion: </strong>These findings demonstrate the long-term safety and efficacy of dynamic tumor-tracking stereotactic body radiotherapy for liver tumors, with an excellent local control rate.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1211-1217"},"PeriodicalIF":2.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with head and neck squamous cell carcinoma: survival analysis based on 2-year follow-up data.","authors":"Yushi Ueki, Yuki Ohno, Shusuke Ohshima, Yusuke Yokoyama, Jo Omata, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Kohei Ohtaki, Kohei Saijo, Ryoko Tanaka, Nao Takahashi, Ryuichi Okabe, Arata Horii","doi":"10.1007/s10147-025-02754-w","DOIUrl":"10.1007/s10147-025-02754-w","url":null,"abstract":"<p><strong>Background: </strong>As a follow-up study to our prospective phase II trial of concurrent chemoradiotherapy (CCRT) with weekly low-dose carboplatin for cisplatin-ineligible patients with head and neck squamous cell carcinoma (HNSCC), we assessed long-term survival (minimum follow-up of 2-year) and subgroup analysis by age and renal function.</p><p><strong>Methods: </strong>A prospective phase II study on CCRT with weekly low-dose carboplatin for cisplatin-ineligible HNSCC in 30 patients who were aged (≥ 75-year-old patients with 40 mL/min estimated glomerular filtration rate [eGFR] or better) or had renal dysfunction (< 75-year-old patients with 30-60 mL/min eGFR) was performed between July 2019 and January 2022 at three tertiary hospitals. Survival outcomes were investigated 2 years after this phase 2 trial were investigated. Furthermore, we compared the treatment outcome between ≥ 75 years group and < 75 years group.</p><p><strong>Results: </strong>The median follow-up time was 41.5 months. The 2-year recurrence-free survival (RFS) and 2-year overall survival (OS) rates of all patients were 70% and 86.7%, respectively. The 2-year RFS and OS of patients ≥ 75 years old was 92.3% and 100%, respectively, whereas those of patients < 75 years old was 52.9% (p = 0.175) and 76% (p = 0.157), respectively, showing no significant differences between the groups.</p><p><strong>Conclusion: </strong>CCRT with weekly low-dose carboplatin in patients with cisplatin-ineligible HNSCC showed favorable survival outcomes irrespective of age and renal function. This study highlights a potentially promising treatment option for cisplatin-ineligible HNSCC patients.</p><p><strong>Trial registration: </strong>jRCTs031190028.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1136-1142"},"PeriodicalIF":2.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of postoperative adjuvant chemotherapy with oxaliplatin for elderly patients: results from the CCOG-1302 study.","authors":"Shinichi Umeda, Goro Nakayama, Takayoshi Kishida, Norifumi Hattori, Koki Nakanishi, Haruyoshi Tanaka, Dai Shimizu, Hideki Takami, Masamichi Hayashi, Mitsuro Kanda, Chie Tanaka, Yasuhiro Kodera","doi":"10.1007/s10147-025-02738-w","DOIUrl":"10.1007/s10147-025-02738-w","url":null,"abstract":"<p><strong>Background: </strong>Postoperative adjuvant chemotherapy using oxaliplatin in addition to 5-FU-based anticancer agents has become the standard treatment for colorectal cancer, however, there is insufficient evidence regarding the efficacy and safety of oxaliplatin combination therapy in the elderly patients. In this study, retrospective analysis of the results from the CCOG-1302 study was performed to confirm them.</p><p><strong>Methods: </strong>The patients in the CAPOX continuous (8 courses of CAPOX) and intermittent (2 courses of CAPOX + 4 courses of capecitabine + 2 courses of CAPOX) treatment arms in the CCOG-1302 study were divided into two groups, namely, the elderly (≥ 70) and non-elderly (< 70 years) groups. The adverse events, residual peripheral sensory neuropathy (PSN) and prognosis were analyzed.</p><p><strong>Results: </strong>The incidence of grade 3 or higher hematologic and non-hematologic toxicities in the continuous and intermittent treatment arm were not significantly different between the elderly and non-elderly groups. During the follow-up period, the percentages of grade I or higher PSN residuals were significantly higher among the elderly individuals in the continuous treatment arm at years 2, 3, 4, and 5. On the other hand, PSN decreased over time in the intermittent treatment arm as well as in the elderly and non-elderly patients. The 3-year DFS was not significantly different between the elderly and non-elderly groups in the continuous and intermittent treatment arms.</p><p><strong>Conclusion: </strong>Oxaliplatin combination chemotherapy can be safely administered to elderly patients. In addition, intermittent administration may be more useful in elderly individuals for the prevention of PSN.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1174-1182"},"PeriodicalIF":2.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12122561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse events of hepatic function disorder in Japanese patients with radically unresectable or metastatic renal cell carcinoma treated with pembrolizumab plus axitinib: a post-marketing surveillance study.","authors":"Mototsugu Oya, Shotaro Yasuoka, Takuto Tokudome, Toshihiko Minegishi, Masahiro Hamada, Masahiko Ozaki, Shinichiroh Maekawa, Yuichiro Ito","doi":"10.1007/s10147-025-02708-2","DOIUrl":"10.1007/s10147-025-02708-2","url":null,"abstract":"<p><strong>Background: </strong>Post-marketing surveillance focusing on hepatic function disorder was requested owing to its higher incidence in the pembrolizumab plus axitinib group than in the sunitinib group in KEYNOTE-426. We aimed to evaluate the prevalence and risk factors of adverse events (AEs) of hepatic function disorder in patients with unresectable/metastatic renal cell carcinoma (RCC) treated with pembrolizumab plus axitinib in real-world clinical practice in Japan.</p><p><strong>Methods: </strong>Patients were observed for 9 months after starting treatment with pembrolizumab plus axitinib.</p><p><strong>Results: </strong>In total, 193 patients were included in the safety analysis set (median age, 70 years). Most patients did not have a history of hepatic function disorder before starting treatment (96.4%, 186/193). The median treatment period was 27.1 weeks. At the 9-month data cut-off, 62.2% (120/193) of patients discontinued treatment, the most common reason being any AE in 31.1% (60/193). The incidence of AEs of hepatic function disorder was 30.1% (58/193) for any grade and 15.0% (29/193) for grade ≥ 3. Most AEs of hepatic function disorder occurred within 3 months from starting treatment. AEs of hepatic function disorder were the reason for discontinuation of pembrolizumab in 9.3% (18/193) of patients; axitinib, 7.3% (14/193); and both pembrolizumab and axitinib, 5.2% (10/193). No background factors were identified as being associated with the occurrence of AEs of hepatic function disorder.</p><p><strong>Conclusion: </strong>There were no new safety signals for AEs of hepatic function disorder, and the incidence was consistent with that reported in KEYNOTE-426, in Japanese patients with radically unresectable/metastatic RCC treated with pembrolizumab plus axitinib.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1229-1236"},"PeriodicalIF":2.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12122596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collaborative frontiers in pediatric neuro-oncology: establishing an international tumor board for enhanced care and global impact.","authors":"Margaret Shatara, Nicole M Brossier, Andrew Cluster, Ali Y Mian, Sonika Dahiya, Amy E Armstrong, Angela C Hirbe, David H Gutmann, Kenneth Aldape, Mohamed S Abdelbaki","doi":"10.1007/s10147-025-02793-3","DOIUrl":"10.1007/s10147-025-02793-3","url":null,"abstract":"<p><strong>Background: </strong>Central nervous system tumors are the leading cause of cancer-related mortality in children, with significant disparities in diagnostic and treatment capabilities between low- and middle-income countries and high-income countries. This study outlines the establishment of an international neuro-oncology tumor board to address these gaps.</p><p><strong>Methods: </strong>The tumor board was initiated in January 2021 through a partnership between Washington University in St. Louis, USA, and nine institutions, ultimately expanding to 39 institutions across 25 countries. Monthly virtual meetings facilitated multi-disciplinary case reviews offering diagnostic and management recommendations. A retrospective analysis of 29 sessions over three years was conducted, and a cross-sectional web-based survey among participants assessed their experiences and satisfaction.</p><p><strong>Results: </strong>From January 2021 to December 2023, 101 cases were reviewed. The most diagnoses were low-grade gliomas (23.4%) and neurofibromatosis type 1 and 2 (32.7%). Newly diagnosed cases comprised 51%, while 40% involved recurrent or progressive disease, and 9% were inquiries during ongoing therapy. Recommendations predominantly addressed therapeutic strategies (60.7%). Advanced diagnostics, such as methylation profiling, refined diagnoses in several cases. The survey, with a 35% response rate, showed high satisfaction, with 91% finding the meetings educational. Barriers included time constraints (71%) and conflicting commitments (27%).</p><p><strong>Conclusion: </strong>This initiative, to our knowledge, represents the largest international pediatric neuro-oncology tumor board. Multidisciplinary discussions improved diagnostic precision, informed therapeutic decision-making and facilitated educational exchange. Participants reported positive impacts on professional development and alignment with institutional needs. Despite challenges, this study highlights telemedicine's potential to bridge resource disparities and improve the outcomes globally.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic factors and treatment patterns of the first recurrence of retroperitoneal liposarcoma.","authors":"Yoshiyuki Matsui, Shintaro Iwata, Konosuke Moritani, Aiko Maejima, Satoshi Nara, Yukinori Yamagata, Motokiyo Komiyama, Satoshi Kamio, Kan Yonemori, Akira Kawai, Hiroyuki Fujimoto","doi":"10.1007/s10147-025-02790-6","DOIUrl":"https://doi.org/10.1007/s10147-025-02790-6","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to identify prognostic factors and treatment patterns at the first recurrence of retroperitoneal liposarcoma (LPS).</p><p><strong>Methods: </strong>Medical records of 150 patients who underwent resection for primary retroperitoneal LPS were reviewed. Of the 94 patients with local or distant recurrence, prognostic factors and treatment approaches were retrospectively analyzed.</p><p><strong>Results: </strong>At recurrence, 41 patients underwent surgery, 12 received radiation, 23 received chemotherapy, 12 were under active surveillance, and 6 received best supportive care. In univariate analysis, well-differentiated primary tumors predicted better overall survival (OS) compared to dedifferentiated tumors (p = 0.004). Conversely, shorter recurrence-free survival (RFS) after initial surgery, smaller recurrent tumors at treatment, and high neutrophil-to-lymphocyte ratio (NLR) at recurrence were associated with poorer OS (p = 0.0418, 0.007, and 0.0475, respectively). Treatment decisions were influenced by RFS, time from recurrence to treatment, initial tumor differentiation, recurrence site, and multiplicity. Among those who had surgery for recurrence, 29.2% (12/41) showed a change in tumor differentiation. RFS was a significant predictor of this change (p = 0.026). Additionally, NLR at recurrence and the waiting period from recurrence to treatment were significant prognostic factors in surgically treated patients (p = 0.005 and 0.028, respectively).</p><p><strong>Conclusions: </strong>RFS, timing of treatment, initial tumor differentiation, and recurrence characteristics influence treatment choices at first recurrence. RFS may predict changes in tumor differentiation, while NLR at recurrence and the waiting period from recurrence to treatment are important prognostic indicators in patients undergoing surgery.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}